Both <i>in vivo</i> and <i>in vitro</i> assays confirmed that Vicenin-2 modulates the IL-17RA/NF-κB pathway, suppressing the expression of inflammatory mediators and matrix metalloproteinases.<h4>Discussion</h4>Vicenin-2 alleviates LL-37-induced rosacea-like inflammation by regulating the IL-17RA/NF-κB pathway and exerting multi-target anti-inflammatory and immunomodulatory effects, suggesting its potential as a novel therapeutic agent for rosacea. The gene discussed is NFKB1; the disease is rosacea.